JOHNSON & JOHNSON JNJ
NYSE · XNYS · stock
Chart by TradingView
3/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $94.2B | $26.8B | $63.9B | $19.7B | $81.5B |
| 2024 | $88.8B | $14.1B | $61.4B | $19.8B | $71.5B |
| 2023 | $85.2B | $35.2B | $58.6B | $18.2B | $68.8B |
| 2023 | $80.0B | $17.9B | $55.4B | $17.2B | $76.8B |
| 2022 | $78.7B | $20.9B | $55.3B | $19.8B | $74.0B |
| 2021 | $82.6B | $14.7B | $54.2B | $20.2B | $63.3B |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Source: SEC EDGAR filings · CIK 0000200406 · as of 2025-12-28. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.